{
    "data": [
        {
            "id": "1760042",
            "type": "article",
            "attributes": {
                "publishOn": "2013-10-22T11:00:38-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Next Best Big Pharma?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24634",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "123552",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1760042-the-next-best-big-pharma"
            }
        },
        {
            "id": "1680812",
            "type": "article",
            "attributes": {
                "publishOn": "2013-09-09T08:20:01-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Pipeline Worth Tens Of Billions In Market Capitalization",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "121493",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1680812-regeneron-pipeline-worth-tens-of-billions-in-market-capitalization"
            }
        },
        {
            "id": "1657682",
            "type": "article",
            "attributes": {
                "publishOn": "2013-08-26T15:30:36-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron's Blockbuster Eylea And The Emerging Competition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "120819",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1657682-regenerons-blockbuster-eylea-and-the-emerging-competition"
            }
        },
        {
            "id": "1640052",
            "type": "article",
            "attributes": {
                "publishOn": "2013-08-16T04:55:07-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is The Price Right For This Biotech Favorite?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24663",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "120317",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1640052-is-the-price-right-for-this-biotech-favorite"
            }
        },
        {
            "id": "1623852",
            "type": "article",
            "attributes": {
                "publishOn": "2013-08-09T14:06:21-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron: Q2 Results And Eylea Data Support The Long-Term Thesis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "35761",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1623852-regeneron-q2-results-and-eylea-data-support-the-long-term-thesis"
            }
        },
        {
            "id": "1612522",
            "type": "article",
            "attributes": {
                "publishOn": "2013-08-07T09:11:30-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron's Horse Eylea Triples Its Speed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23183",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "119843",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1612522-regenerons-horse-eylea-triples-its-speed"
            }
        },
        {
            "id": "1523312",
            "type": "article",
            "attributes": {
                "publishOn": "2013-06-26T18:28:09-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron's New Asthma Drug And Its Fierce Competitors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "117990",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1523312-regenerons-new-asthma-drug-and-its-fierce-competitors"
            }
        },
        {
            "id": "1471071",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-30T13:56:00-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron's Blockbuster Drug Eylea And Its Potential Competitors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "116589",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1471071-regenerons-blockbuster-drug-eylea-and-its-potential-competitors"
            }
        },
        {
            "id": "1454651",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-22T15:56:43-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Shareholders Watching Optina Trial Closely",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48551",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1454651-regeneron-shareholders-watching-optina-trial-closely"
            }
        },
        {
            "id": "1429911",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-13T11:24:38-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Regeneron A Value Pick In The Pharma Sector?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "47291",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "115841",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1429911-is-regeneron-a-value-pick-in-the-pharma-sector"
            }
        },
        {
            "id": "1408521",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-07T10:26:43-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron: Solid Q1 Creates Platform For Further Upside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "35761",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "115551",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/1408521-regeneron-solid-q1-creates-platform-for-further-upside"
            }
        },
        {
            "id": "1407031",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-06T17:46:15-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Regeneron's Eylea Became A 'Trump Card' In The Niche AMD Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24433",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "115531",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1407031-how-regenerons-eylea-became-a-trump-card-in-the-niche-amd-market"
            }
        },
        {
            "id": "1375091",
            "type": "article",
            "attributes": {
                "publishOn": "2013-04-26T04:18:54-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "My Number One Ranked Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24634",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "115105",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1375091-my-number-one-ranked-stock"
            }
        },
        {
            "id": "1318201",
            "type": "article",
            "attributes": {
                "publishOn": "2013-04-03T13:43:44-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24433",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "114042",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1318201-lucrative-amd-and-dme-markets-attract-wall-street-to-regeneron-and-other-players"
            }
        }
    ]
}